First-line trials

These trials are for patients that have never had Gleevec before (although some may allow previous adjuvant Gleevec, check the trial details). The intent of these trials is to try to improve on the initial response to therapy. Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.

3 trials found

Imatinib + Regorafenib

A Randomised Trial of Imatinib Alternating With Regorafenib Compared to Imatinib Alone for the First Line Treatment of Advanced Gastrointestinal Stromal Tumour (GIST) (ALT GIST)
Phase: 
2 Drug Category: KIT/PDGFRA inhibitor + VEGF inhibitor
NCT#:
NCT02365441 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Calvary Mater Newcastle Hospital Waratah New South Wales Australia
Prince of Wales Hospital Randwick New South Wales Australia
Princess Alexandra Hospital Woolloongabba Queensland Australia
Ashford Cancer Centre Research Kurrulta Park South Australia Australia
Flinders Medical Centre Bedford Park South Australia Australia
Canberra Hospital Garran Australian Capital Territory Australia
Sir Charles Gairdner Hospital Nedlands Western Australia Australia
Royal Hobart Hospital Hobart Tasmania Australia
Border Medical Oncology Wodonga Victoria Australia
Peninsula South Eastern Haematology & Oncology Group Frankston Victoria Australia
Norwegian Radium Hospital Oslo Norway
National Cancer Center Singapore Singapore
Helsinki University Central Hospital Helsinki Finland
Institut Bergonie Bordeaux Gironde France
Centre Georges Francois Leclerc Dijon France
Centre Léon Bérard Lyon Rhone France
Institut Gustave Roussy Villejuif Val de Narne France
Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Amsterdam Netherlands
Dept of Oncology, Haukeland University Hospital Bergen Norway
Lund University Hospital Lund Sweden
CO L'Hospitalet - Hospital Duran i Reynals Barcelona Spain
National Cancer Institute Bratislava NSW Slovakia
Royal Marsden Hospital - Chelsea London UK
University Hospital Birmingham - Queen Elizabeth Hospital Birmingham UK
Nottingham University Hospitals NHS Trust - Nottingham City Hospital Nottingham UK


Regorafenib (SDH)

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI)
Phase: 
2 Drug Category: SDH-directed
NCT#:
NCT02638766 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Institut Bergonie Bordeaux Gironde France
Centre Léon Bérard Lyon Rhone France
Istituto Nazionale Dei Tumori Milan Italy
Universita Campus Bio-Medico di Roma Rome Italy
Hospital Universitario de Canarias Tenerife Spain
Hospital Vall d'Hebron Barcelona Spain
Hospital Santa Creu i Sant Pau Barcelona Spain
University Hospital La Paz Madrid Spain
hospital Universitario Miguel Servet Zaragosa Spain
Instituto di Candiolo - IRCSS Torino Italy
Hospital de Cruces Barakaldo Spain
Hospital Universitario Gregorio Maranon Madrid Spain
Hospital Universitario Virgen de la Macarena Sevilla Spain
Instituto Valencia de Oncologia Valencia Spain
Hospital Virgen del Rocio Sevilla Spain


Surgery

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Phase: 
Drug Category: None
NCT#:
NCT04557969 Conditions: Gastrointestinal Stromal Tumor
Status:
Recruiting
Site
City
State
Country
Naytional Cancer Institute Bethesda MD USA


3 trials found